Welcome to our dedicated page for Simulations Plus news (Ticker: SLP), a resource for investors and traders seeking the latest updates and insights on Simulations Plus stock.
Simulations Plus Inc (NASDAQ: SLP) is a leading provider of modeling software and consulting services for pharmaceutical research and regulatory compliance. This page serves as the definitive source for official company announcements and market-moving developments.
Access real-time updates on earnings reports, strategic partnerships, product innovations, and regulatory milestones. Our curated news collection helps stakeholders track advancements in ADMET prediction tools, PBPK modeling capabilities, and drug development consulting services.
Discover press releases covering software updates, research collaborations, and industry recognitions. Stay informed about initiatives impacting pharmaceutical R&D efficiency and global regulatory submissions. Content is verified through primary sources to ensure accuracy and relevance.
Bookmark this page for streamlined access to Simulations Plus' latest business developments. Combine these updates with our comprehensive company profile for informed analysis of SLP's market position in computational pharmacology solutions.
Simulations Plus, Inc. (NASDAQ: SLP) announced a funded contract with the FDA to advance in vitro and physiology-based pharmacokinetics (PBPK) models for inhaled drug development. This collaboration aims to enhance the Pulmonary Compartmental Absorption and Transit (PCAT™) model, using data from healthy and patient samples to validate and propose alternatives for bioequivalence studies. The project is a continuation of Simulations Plus's commitment to improving drug development processes while minimizing the need for human and animal studies.
Simulations Plus, a leader in pharmaceutical modeling software, reported a 16% revenue increase year-over-year to $53.9 million for FY 2022. Diluted earnings per share rose 28% to $0.60. Q4 revenue surged 19% to $11.7 million, driven by a 30% increase in services revenue, while gross margin improved to 77%. For FY 2023, the company projects a revenue between $59.3 million and $62.0 million, signaling expected growth of 10% to 15%.
Simulations Plus (NASDAQ: SLP) has declared a quarterly cash dividend of
Simulations Plus has been a leader in the biosimulation market for over 25 years, providing essential software and consulting services to support drug discovery and development.
Simulations Plus (NASDAQ: SLP) has announced the launch of version 9.8.3 of its GastroPlus software, enhancing its physiologically based biopharmaceutics modeling capabilities. Key updates include improved reporting templates for Monolix, new validated disease populations for NAFL and NASH, a swine PBPK model for veterinary research, and flexible dosing regimen handling. The company aims to strengthen software interoperability and provide researchers with advanced simulation tools. This release reflects the company's ongoing commitment to integrating machine learning and quantitative systems pharmacology in drug development.
Simulations Plus (NASDAQ: SLP) is set to announce its fourth quarter and full year financial results for fiscal year 2022, ending August 31, 2022, following market closure on October 26, 2022. The company will host a conference call at 5:00 PM ET that day, inviting all interested parties to participate. The call can be accessed via registration or by calling in. Simulations Plus has been a key player in the biosimulation market for over 25 years, providing essential software and consulting services for drug discovery and regulatory submissions.
Simulations Plus, Inc. (Nasdaq: SLP) has announced that CEO Shawn O’Connor will present at the Sidoti Fall Small Cap Investor Conference on September 22, 2022, at 10:45 a.m. ET. The conference will be held virtually on September 21-22, 2022, where O’Connor will engage with investors throughout the day. The presentation will be webcast live and available for replay on the Simulations Plus investor page. For additional details about the conference, visit the conference website or contact Brian Siegel at Hayden IR.
Simulations Plus, a leader in biosimulation software, will present at Baird’s 2022 Global Healthcare Conference on September 14, 2022, at 2:00 p.m. ET. CEO Shawn O’Connor will discuss the company's advancements in modeling and simulation for pharmaceutical safety and efficacy. The session will be webcast live and available for replay on the Simulations Plus website. Established for over 25 years, Simulations Plus provides innovative solutions to major pharmaceutical and regulatory agencies worldwide.
Simulations Plus has launched ILDsym™ version 1A, a quantitative systems pharmacology modeling software aimed at enhancing therapy development for Interstitial Lung Disease (ILD)
Simulations Plus (NASDAQ: SLP) announces a collaboration with a large pharmaceutical company to enhance its ADMET Predictor® platform. The partner will provide tens of thousands of proprietary pKa measurements to improve prediction accuracy and extend chemical coverage. This initiative aims to reinforce ADMET Predictor as the leading property prediction tool in drug discovery, leveraging advanced machine learning techniques. The collaboration is expected to significantly advance predictive modeling within the pharmaceutical sector.
Simulations Plus (NASDAQ: SLP) announced the presentation of five scientific posters at the PAGE conference in Ljubljana, Slovenia, from June 28 to July 1, 2022. The conference gathered over 600 scientists focused on data analysis through a population approach. Dr. Jonathan Chauvin emphasized the importance of the event for discussing advancements in modeling and simulation, particularly the MonolixSuite platform. New developments presented include algorithms aimed at enhancing NLME modeling, contributing to the increasing adoption of MonolixSuite.
FAQ
What is the current stock price of Simulations Plus (SLP)?
What is the market cap of Simulations Plus (SLP)?
